UnknownPhase 3

Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes

Lead sponsor

Rabin Medical Center

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

Study population

Prediabetes / glucose intolerance

Eligibility highlights

•BMI ≥27

Primary endpoint

•Postprandial glucose

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02016846

Org study ID0209-13

Timeline

Milestones

Study first posted2013-12-20estimated

Last update posted2013-12-24estimated

Study start2014-01 (month precision)

Primary completion2015-01estimated (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Prediabetes / glucose intolerance

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Planned treatment with T. Prednisone in dosage >0.5 mg/kg for two weeks or more.

•Age >18 years

•Body mass index >27 kg/m2 OR 1st degree relative with type 2 diabetes mellitus OR hypertension OR hyperlipidemia OR gestational diabetes in the past OR diagnosis of polycystic ovary syndrome.

Exclusion criteria

•Glycosylated hemoglobin A1c >6.5%

•Diagnosis of diabetes mellitus or treatment with anti-glycemic drug

•Pancreatitis (acute or chronic) in the past

•Active malignancy

•Medullary thyroid carcinoma or multiple endocrine neoplasm type 2 of the patient or of 1st degree relative

•Pregnancy

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

Glucose levels 2 hours after 75 gr OGTT

Time frame:6 weeks

Postprandial glucose

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.